A New Dawn: Health Canada Approves Second Drug to Slow Alzheimer’s Progression

The landscape of dementia care in Canada reached a significant turning point in 2026. Following the landmark approval of lecanemab (Leqembi) in late 2025, Health Canada has officially authorized donanemab, marketed under the brand name Kisunla, as the second disease-modifying therapy for Alzheimer’s disease. This development represents a “hopeful milestone” for thousands of Canadians navigating the early stages of cognitive decline.

While Alzheimer’s disease remains a complex and currently incurable condition, the arrival of a second amyloid-targeting therapy offers renewed optimism. By focusing on the biological roots of the disease rather than just managing symptoms, these medications represent a paradigm shift in how we approach one of the most challenging health crises of our time.

Understanding Donanemab: How It Works

Donanemab, developed by the American pharmaceutical giant Eli Lilly, functions as a monoclonal antibody. Its primary mechanism is to target and clear amyloid plaques—the sticky, toxic protein buildup that accumulates in the brain during the early stages of Alzheimer’s disease.

For years, researchers have theorized that the accumulation of these plaques contributes to the breakdown of neural communication, leading to the memory loss and cognitive impairment characteristic of the disease. By reducing these plaques, donanemab aims to slow the clinical decline of patients.

Key Clinical Findings

In clinical trials, the results were promising for those in the early symptomatic stages of the disease:

Slowing Cognitive Decline: Participants with less advanced disease showed a 35% slowing of decline on the integrated Alzheimer’s Disease Rating Scale (iADRS) over an 18-month period.

Overall Population Benefit: Across the broader study population, the drug demonstrated a 22% slowing of disease progression.

• Unique Dosing Strategy: One of the most distinct features of Kisunla is its treatment protocol. Patients may be able to stop treatment once amyloid plaques are cleared. Eli Lilly noted that some trial participants discontinued therapy after just six months, with nearly half stopping by the 12-month mark.

A “Hopeful Milestone” for Canadian Patients

The Alzheimer Society of Canada has lauded the approval as a vital step forward. CEO Christina Scicluna emphasized that while these drugs are not a cure, they demonstrate the profound progress made through decades of research and advocacy.

Dr. Sharon Cohen, a neurologist and medical director at the Toronto Memory Program, echoed this sentiment. She highlighted that for patients who are still living independently and maintaining robust lives, the ability to “change the downward trajectory” of the disease is of paramount importance. It provides a window of time for individuals to maintain their autonomy and continue engaging with their families and communities.

Important Considerations and Safety Profiles

While the news is undeniably positive, it is essential for patients and their families to understand the limitations and risks associated with this new therapy.

The APOE4 Genetic Factor

Health Canada has placed specific limitations on the prescription of donanemab. The drug is currently authorized for use in adults who do not carry the APOE4 gene. This genetic variant, found in approximately one-fifth of the global population, is known to significantly increase the risk of dementia. Regulatory bodies are cautious about the interaction between the drug and this specific genetic profile to ensure patient safety.

Potential Side Effects

As with any potent medication, there are risks. A known side effect of amyloid-targeting therapies is amyloid-related imaging abnormalities (ARIA). Eli Lilly notes that this can manifest as temporary swelling or, in some cases, small areas of bleeding in the brain. Patients receiving this treatment will require consistent monitoring via MRI scans to detect and manage these potential issues early.

The Path to Accessibility: Funding and Coverage

The arrival of a second disease-modifying drug brings up a critical question for many families: How will this be paid for?

Currently, Canada’s Drug Agency is in the process of assessing whether donanemab should be included in provincial and territorial drug plans. The Alzheimer Society of Canada is actively advocating for public coverage, but they caution that the transition from regulatory approval to public funding can often take up to two years.

For those with private insurance or extended health benefits, access may be faster. However, the cost of these therapies remains a significant barrier for the average household. The push for equitable access remains a top priority for advocates who believe that life-altering medication should not be limited by a patient’s financial status or province of residence.

Looking Ahead: A New Era of Dementia Care

The approval of donanemab, following closely on the heels of lecanemab, signals that we have moved past the era where Alzheimer’s was treated solely through symptom management. We are now in an era of disease-modifying intervention.

The Importance of Early Detection

Because these drugs are most effective in the early stages of Alzheimer’s, the importance of early diagnosis cannot be overstated. Health systems across Canada are being encouraged to improve screening processes so that patients can be identified and assessed for eligibility before their cognitive decline progresses too far.

A Holistic Approach

It is important to remember that medication is only one piece of the puzzle. The Alzheimer Society of Canada continues to emphasize the need for “practical supports”—counseling, caregiver resources, and community programs—that work in tandem with medical treatments. Navigating an Alzheimer’s diagnosis is a journey that requires a multi-faceted approach, combining cutting-edge science with compassionate human support.

Conclusion

The authorization of donanemab in 2026 is a testament to the power of medical innovation. While we must remain realistic about the fact that this is not a miracle cure, it is undeniably a “hopeful milestone.” It provides patients with early-stage Alzheimer’s the gift of time—time to think, time to remember, and time to remain independent. As we look to the future, the continued evolution of these therapies and the push for universal access will be central to improving the quality of life for Canadians living with dementia.